vs
Healthpeak Properties（DOC）与豪洛捷（HOLX）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是Healthpeak Properties的1.5倍（$1.0B vs $719.4M），Healthpeak Properties净利率更高（73.2% vs 17.1%，领先56.1%），Healthpeak Properties同比增速更快（3.1% vs 2.5%），Healthpeak Properties自由现金流更多（$357.0M vs $215.2M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 1.5%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
DOC vs HOLX — 直观对比
营收规模更大
HOLX
是对方的1.5倍
$719.4M
营收增速更快
DOC
高出0.5%
2.5%
净利率更高
DOC
高出56.1%
17.1%
自由现金流更多
DOC
多$141.8M
$215.2M
两年增速更快
DOC
近两年复合增速
1.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $1.0B |
| 净利润 | $114.0M | $179.1M |
| 毛利率 | — | 56.0% |
| 营业利润率 | 17.4% | 22.6% |
| 净利率 | 73.2% | 17.1% |
| 营收同比 | 3.1% | 2.5% |
| 净利润同比 | 2406.4% | -10.9% |
| 每股收益（稀释后） | $0.16 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCHOLX
| Q4 25 | $719.4M | $1.0B | ||
| Q3 25 | $705.9M | $1.0B | ||
| Q2 25 | $694.3M | $1.0B | ||
| Q1 25 | $702.9M | $1.0B | ||
| Q4 24 | $698.0M | $1.0B | ||
| Q3 24 | $700.4M | $988.0M | ||
| Q2 24 | $695.5M | $1.0B | ||
| Q1 24 | $606.6M | $1.0B |
净利润DOCHOLX
| Q4 25 | $114.0M | $179.1M | ||
| Q3 25 | $-117.1M | $187.2M | ||
| Q2 25 | $31.7M | $194.9M | ||
| Q1 25 | $42.8M | $-17.4M | ||
| Q4 24 | $4.5M | $201.0M | ||
| Q3 24 | $85.9M | $178.6M | ||
| Q2 24 | $146.0M | $194.5M | ||
| Q1 24 | $6.7M | $169.9M |
毛利率DOCHOLX
| Q4 25 | — | 56.0% | ||
| Q3 25 | 58.6% | 55.6% | ||
| Q2 25 | 60.2% | 56.3% | ||
| Q1 25 | 61.1% | 37.5% | ||
| Q4 24 | 60.3% | 56.8% | ||
| Q3 24 | 60.0% | 56.4% | ||
| Q2 24 | 60.6% | 55.4% | ||
| Q1 24 | 59.8% | 53.3% |
营业利润率DOCHOLX
| Q4 25 | 17.4% | 22.6% | ||
| Q3 25 | 9.2% | 22.6% | ||
| Q2 25 | 5.7% | 24.9% | ||
| Q1 25 | 7.7% | -0.7% | ||
| Q4 24 | -2.2% | 22.5% | ||
| Q3 24 | 14.1% | 23.3% | ||
| Q2 24 | 22.3% | 24.1% | ||
| Q1 24 | 3.7% | 20.7% |
净利率DOCHOLX
| Q4 25 | 73.2% | 17.1% | ||
| Q3 25 | -16.6% | 17.8% | ||
| Q2 25 | 4.6% | 19.0% | ||
| Q1 25 | 6.1% | -1.7% | ||
| Q4 24 | 0.7% | 19.7% | ||
| Q3 24 | 12.3% | 18.1% | ||
| Q2 24 | 21.0% | 19.2% | ||
| Q1 24 | 1.1% | 16.7% |
每股收益（稀释后）DOCHOLX
| Q4 25 | $0.16 | $0.79 | ||
| Q3 25 | $-0.17 | $0.84 | ||
| Q2 25 | $0.05 | $0.86 | ||
| Q1 25 | $0.06 | $-0.08 | ||
| Q4 24 | $0.02 | $0.87 | ||
| Q3 24 | $0.12 | $0.75 | ||
| Q2 24 | $0.21 | $0.82 | ||
| Q1 24 | $0.01 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $2.4B |
| 总债务越低越好 | $9.8B | $2.5B |
| 股东权益账面价值 | $7.5B | $5.2B |
| 总资产 | $20.3B | $9.2B |
| 负债/权益比越低杠杆越低 | 1.31× | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资DOCHOLX
| Q4 25 | $467.5M | $2.4B | ||
| Q3 25 | $91.0M | $2.2B | ||
| Q2 25 | $89.4M | $1.9B | ||
| Q1 25 | $70.6M | $1.6B | ||
| Q4 24 | $119.8M | $2.0B | ||
| Q3 24 | $180.4M | $2.3B | ||
| Q2 24 | $106.9M | $2.4B | ||
| Q1 24 | $101.8M | $2.2B |
总债务DOCHOLX
| Q4 25 | $9.8B | $2.5B | ||
| Q3 25 | $9.1B | $2.5B | ||
| Q2 25 | $9.0B | $2.5B | ||
| Q1 25 | $8.9B | $2.5B | ||
| Q4 24 | $8.7B | $2.5B | ||
| Q3 24 | $8.6B | $2.5B | ||
| Q2 24 | $8.6B | $2.5B | ||
| Q1 24 | $8.8B | $2.6B |
股东权益DOCHOLX
| Q4 25 | $7.5B | $5.2B | ||
| Q3 25 | $7.6B | $5.0B | ||
| Q2 25 | $7.9B | $4.8B | ||
| Q1 25 | $8.2B | $4.6B | ||
| Q4 24 | $8.4B | $4.8B | ||
| Q3 24 | $8.6B | $5.1B | ||
| Q2 24 | $8.8B | $5.0B | ||
| Q1 24 | $8.9B | $4.8B |
总资产DOCHOLX
| Q4 25 | $20.3B | $9.2B | ||
| Q3 25 | $19.6B | $9.0B | ||
| Q2 25 | $19.8B | $8.8B | ||
| Q1 25 | $19.8B | $8.5B | ||
| Q4 24 | $19.9B | $8.7B | ||
| Q3 24 | $20.0B | $9.2B | ||
| Q2 24 | $20.2B | $8.9B | ||
| Q1 24 | $20.5B | $8.7B |
负债/权益比DOCHOLX
| Q4 25 | 1.31× | 0.48× | ||
| Q3 25 | 1.20× | 0.50× | ||
| Q2 25 | 1.14× | 0.52× | ||
| Q1 25 | 1.08× | 0.55× | ||
| Q4 24 | 1.04× | 0.53× | ||
| Q3 24 | 1.00× | 0.49× | ||
| Q2 24 | 0.98× | 0.51× | ||
| Q1 24 | 0.99× | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $229.9M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $215.2M |
| 自由现金流率自由现金流/营收 | 49.6% | 20.5% |
| 资本支出强度资本支出/营收 | 124.4% | 1.4% |
| 现金转化率经营现金流/净利润 | 10.99× | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流DOCHOLX
| Q4 25 | $1.3B | $229.9M | ||
| Q3 25 | $315.0M | $355.1M | ||
| Q2 25 | $363.5M | $343.3M | ||
| Q1 25 | $279.4M | $169.4M | ||
| Q4 24 | $1.1B | $189.3M | ||
| Q3 24 | $318.2M | $367.0M | ||
| Q2 24 | $316.2M | $405.8M | ||
| Q1 24 | $152.6M | $292.4M |
自由现金流DOCHOLX
| Q4 25 | $357.0M | $215.2M | ||
| Q3 25 | — | $341.4M | ||
| Q2 25 | — | $330.5M | ||
| Q1 25 | — | $153.9M | ||
| Q4 24 | $333.7M | $172.5M | ||
| Q3 24 | — | $350.6M | ||
| Q2 24 | — | $385.3M | ||
| Q1 24 | — | $279.6M |
自由现金流率DOCHOLX
| Q4 25 | 49.6% | 20.5% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 32.3% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | 47.8% | 16.9% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | — | 38.1% | ||
| Q1 24 | — | 27.5% |
资本支出强度DOCHOLX
| Q4 25 | 124.4% | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | 105.6% | 1.6% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 1.3% |
现金转化率DOCHOLX
| Q4 25 | 10.99× | 1.28× | ||
| Q3 25 | — | 1.90× | ||
| Q2 25 | 11.48× | 1.76× | ||
| Q1 25 | 6.52× | — | ||
| Q4 24 | 235.43× | 0.94× | ||
| Q3 24 | 3.71× | 2.05× | ||
| Q2 24 | 2.17× | 2.09× | ||
| Q1 24 | 22.85× | 1.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
